Noxopharm bags new funding to fuel game-changing cancer treatments
Noxopharm Limited, an Australian biotech powerhouse, has successfully raised A$2.1 million in funding through the issuance of convertible notes to sophisticated investors. This funding will ... Read More
Noxopharm doses first patient in NOXCOVID-1 clinical trial with Veyonda
Australian drug development company Noxopharm has dosed the first patient in the phase 1 NOXCOVID-1 clinical trial with Veyonda, its lead pipeline candidate, in hospitalized ... Read More